Bulls REASONS TO BUY
December 06, 2013
(The DIV-Net, 11/20/13)
I didn't actually plan on purchasing any more equities for the month of September. I was quite satisfied with initiating an investment in Exxon Mobil Corporation (XOM) and the addition...(read more)
(The DIV-Net, 11/1/13)
I'm confounded lately. The S&P closed at an all-time high this past Friday - finishing at 1,759.77. An incredible run so far in 2013 has the index up 23.4 percent YTD. Although the broader market's...(read more)
(Stock Blog Hub, 12/11/12)
Baxter International (BAX) recently revealed critical Phase I/III study outcomes analyzing the efficacy and safety of BAX 326. This is an investigational recombinant factor IX protein, which...(read more)
Baxter International (BAX) Company Overview
Headquartered in Deerfield, Illinois, Baxter International (NDAQ: BAX) is a global diversified medical products and services company with expertise in medical devices, pharmaceuticals, and biotechnology, used to treat complex medical conditions, including hemophilia, immune disorders, cancer, infectious diseases, kidney disease, and trauma. With 48,000 employees, manufacturing centers in 27 countries, and operations in over 100 countries, the firm operates in three business segments: BioScience (pharmaceuticals derived from blood plasma), Medication Delivery (products for intravenous therapy), and Renal (dialysis equipment and solutions for patients with kidney failure).
Led by hemophilia drug ADVATE and immune deficiency drug IVIG, BioScience has been Baxter's fastest-growing segment in recent years. The Renal segment specializes in dialysis machines for people with terminal kidney disease or failure and has achieved high growth in emerging markets where many people are under-treated.(Read more at Wikinvest )
What's in this BAX analysis on Wikinvest...